<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04404725</url>
  </required_header>
  <id_info>
    <org_study_id>EX-MKTG-110</org_study_id>
    <nct_id>NCT04404725</nct_id>
  </id_info>
  <brief_title>Comparing Biofinity Toric Multifocal to Ultra Multifocal for Astigmatism</brief_title>
  <official_title>Comparing Biofinity Toric Multifocal to Ultra Multifocal for Astigmatism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coopervision, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coopervision, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to compare the handling and performance of Biofinity Toric&#xD;
      Multifocal to Ultra Multifocal for Astigmatism.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the study is to compare the handling and performance of Biofinity Toric&#xD;
      Multifocal to Ultra Multifocal for Astigmatism. This is a prospective, randomized,&#xD;
      participant masked, crossover, bilateral dispensing study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 6, 2020</start_date>
  <completion_date type="Actual">July 29, 2021</completion_date>
  <primary_completion_date type="Actual">July 29, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lens Handling at Insertion</measure>
    <time_frame>One month</time_frame>
    <description>Subjective at-home ratings of lens handling for insertion, using a 0-10 scale (0-Very difficult, 10 - Very easy).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Astigmatism</condition>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>comfilcon A then samfilcon A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were randomized to wear comfilcon A for one month then Samfilcon A for one month in this randomized, bilateral cross-over study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>samfilcon A then comfilcon A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects were randomized to wear samfilcon A for one month then comfilcon A for one month in this randomized, bilateral cross-over study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>comfilcon A</intervention_name>
    <description>Subjects will be randomized to wear comfilcon A for one month.</description>
    <arm_group_label>comfilcon A then samfilcon A</arm_group_label>
    <arm_group_label>samfilcon A then comfilcon A</arm_group_label>
    <other_name>Biofinity Toric Multifocal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Samfilcon A</intervention_name>
    <description>Subjects will be randomized to wear samfilcon A for one month.</description>
    <arm_group_label>comfilcon A then samfilcon A</arm_group_label>
    <arm_group_label>samfilcon A then comfilcon A</arm_group_label>
    <other_name>Ultra Multifocal for Astigmatism</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Is at least 42 years of age and has full legal capacity to volunteer;&#xD;
&#xD;
          2. Has read and signed an information consent letter;&#xD;
&#xD;
          3. Self reports having a full eye examination in the previous two years;&#xD;
&#xD;
          4. Anticipates being able to wear the study lenses for at least 8 hours a day, 5 days a&#xD;
             week;&#xD;
&#xD;
          5. Is willing and able to follow instructions and maintain the appointment schedule;&#xD;
&#xD;
          6. Habitually wears soft contact lens for the past 3 months minimum;&#xD;
&#xD;
          7. Has refractive astigmatism of at least -0.75DC;&#xD;
&#xD;
          8. Is presbyopic and requires a reading addition of at least +0.75D;&#xD;
&#xD;
          9. Can be fit and achieve binocular distance vision of at least 20/30 Snellen (or +0.20&#xD;
             logMAR) which participants also deem to be 'acceptable', with the available study lens&#xD;
             parameters (sphere +4 to -6; cylinder -0.75 to -1.75DC; near addition +0.75 to +2.50).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Is participating in any concurrent clinical or research study;&#xD;
&#xD;
          2. Habitually wears one of the study contact lenses;&#xD;
&#xD;
          3. Has any known active* ocular disease and/or infection;&#xD;
&#xD;
          4. Has a systemic condition that in the opinion of the investigator may affect a study&#xD;
             outcome variable;&#xD;
&#xD;
          5. Is using any systemic or topical medications that in the opinion of the investigator&#xD;
             may affect contact lens wear or a study outcome variable;&#xD;
&#xD;
          6. Has known sensitivity to the diagnostic sodium fluorescein and/or the care product&#xD;
             Opti-Free PureMoist being used in the study;&#xD;
&#xD;
          7. Self-reports as pregnant, lactating or planning a pregnancy at the time of enrolment;&#xD;
&#xD;
          8. Has undergone refractive error surgery. * For the purposes of this study, active&#xD;
             ocular disease is defined as infection or inflammation which requires therapeutic&#xD;
             treatment. Mild (i.e. not considered clinically relevant) lid abnormalities&#xD;
             (blepharitis, meibomian gland dysfunction, papillae), corneal and conjunctival&#xD;
             staining and dry eye are not considered active ocular disease. Neovascularization and&#xD;
             corneal scars are the result of previous hypoxia, infection or inflammation and are&#xD;
             therefore not active.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lyndon Jones, PhD FCOptom</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Waterloo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fiona Soong</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eyes on Sheppard Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adam Keech</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oakley Eyecare</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Howard Dolman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dolman Eyecare Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristin Heeney</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spadina Optometry</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Nelson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Waverly Eye Care Centre &amp; EyeGym</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Kreuzer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glasses Half Full</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lyndon Jones</name>
      <address>
        <city>Waterloo</city>
        <state>Ontorio</state>
        <zip>N2L 3G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 22, 2020</study_first_submitted>
  <study_first_submitted_qc>May 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2020</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Astigmatism</mesh_term>
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

